Journal ArticleDOI
Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.
Zbigniew M. Szczepiorkowski,Jeffrey L. Winters,Nicholas Bandarenko,Haewon C. Kim,Michael L. Linenberger,Marisa B. Marques,Ravindra Sarode,Joseph E. Schwartz,Robert Weinstein,Beth H. Shaz +9 more
TLDR
The Fourth ASFA Special Issue is significantly modified in comparison to the previous editions and a new concept of a fact sheet has been introduced that succinctly summarizes the evidence for the use of therapeutic apheresis.Abstract:
The American Society for Apheresis (ASFA) Apheresis Applications Committee is charged with a review and categorization of indications for therapeutic apheresis. This elaborate process had been undertaken every 7 years resulting in three prior publications in 1986, 1993, and 2000 of "The ASFA Special Issues." This article is the integral part of the Fourth ASFA Special Issue. The Fourth ASFA Special Issue is significantly modified in comparison to the previous editions. A new concept of a fact sheet has been introduced. The fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis. A detailed description of the fact sheet is provided. The article consists of 53 fact sheets devoted to each disease entity currently categorized by the ASFA. Categories I, II, and III are defined as previously in the Third Special Issue. However, a few new therapeutic apheresis modalities, not yet approved in the United States or are currently in clinical trials, have been assigned category P (pending) by the ASFA Clinical Categories Subcommittee. The diseases assigned to category IV are discussed in a separate article in this issue.read more
Citations
More filters
Book ChapterDOI
Hematological Problems in Pediatric Intensive Care
TL;DR: Hematologic abnormalities are common in children admitted to pediatric intensive care units (PICUs) and some are primary and related to the underlying hematologic disease in the child.
Journal ArticleDOI
The Agenda for Familial Hypercholesterolemia A Scientific Statement From the American Heart Association
Samuel S. Gidding,Mary Ann Champagne,Sarah D. de Ferranti,Joep C. Defesche,Matthew K. Ito,Joshua W. Knowles,Brian W. McCrindle,Frederick J. Raal,Daniel J. Rader,Raul D. Santos,Maria Lopes-Virella,Gerald F. Watts,Anthony S. Wierzbicki +12 more
TL;DR: Drug discovery has linked enhancement of LDL receptor function to LDL-C lowering and successful prevention of ischemic heart disease, first with statins and now with newer drugs that affect LDL receptors function in other ways, including those that impair PCSK9 regulation of LDL receptors recycling.
Journal ArticleDOI
Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome
Barbara Sjouke,D. Meeike Kusters,Iris Kindt,Joost Besseling,Joep C. Defesche,Eric J.G. Sijbrands,Jeanine E. Roeters van Lennep,Anton F. H. Stalenhoef,Albert Wiegman,Jacqueline de Graaf,Sigrid W. Fouchier,John J. P. Kastelein,G. Kees Hovingh +12 more
TL;DR: The prevalence of molecularly defined hoADH is much higher and the clinical phenotype is more variable than previously assumed and an uniform definition ofHoADH either as a phenotypic or molecular entity is warranted in order to identify patients who are considered to be eligible for these novel agents.
Journal ArticleDOI
Issues in Hypertriglyceridemic Pancreatitis - An Update
TL;DR: Diet, lifestyle changes, and control of secondary factors are key to the treatment, and medications are useful adjuncts to the long-term management of TG levels.
Journal ArticleDOI
Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation
Gerald F. Watts,Samuel S. Gidding,Anthony S. Wierzbicki,Peter P. Toth,Peter P. Toth,Rodrigo Alonso,W. Virgil Brown,Eric Bruckert,Joep C. Defesche,Khoo Kah Lin,Michael Livingston,Pedro Mata,Klaus G. Parhofer,Frederick J. Raal,Raul D. Santos,Eric J.G. Sijbrands,William G. Simpson,David R. Sullivan,Andrey V. Susekov,Brian Tomlinson,Albert Wiegman,Shizuya Yamashita,John J.P. Kastelein +22 more
TL;DR: Recommendations on treatment are based on risk stratification, management of non-cholesterol risk factors, and safe and effective use of LDL lowering therapies, and the use of emerging therapies for FH is foreshadowed.
References
More filters
Journal ArticleDOI
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt,Andrew D Oxman,Gunn Elisabeth Vist,Regina Kunz,Yngve Falck-Ytter,Pablo Alonso-Coello,Holger J. Schünemann +6 more
TL;DR: The advantages of the GRADE system are explored, which is increasingly being adopted by organisations worldwide and which is often praised for its high level of consistency.
Journal ArticleDOI
Grading quality of evidence and strength of recommendations.
David C. Atkins,Dana Best,Peter A. Briss,Martin P Eccles,Yngve Falck-Ytter,Signe Flottorp,Gordon H. Guyatt,Robin Harbour,Margaret C Haugh,David Henry,Suzanne Hill,Roman Jaeschke,Gillian Leng,Alessandro Liberati,Nicola Magrini,James Mason,Philippa Middleton,Jacek Mrukowicz,Dianne L. O'Connell,Andrew D Oxman,Bob Phillips,Holger J. Schünemann,Tessa Tan-Torres Edejer,H. Varonen,Gunn Elisabeth Vist,John W Williams,Stephanie Zaza +26 more
TL;DR: A system for grading the quality of evidence and the strength of recommendations that can be applied across a wide range of interventions and contexts is developed, and a summary of the approach from the perspective of a guideline user is presented.
Journal ArticleDOI
Systemic lupus erythematosus
Jessica J Manson,Anisur Rahman +1 more
TL;DR: Systemic lupus erythematosus is a relapsing and remitting disease, and treatment aims are threefold: managing acute periods of potentially life-threatening ill health, minimizing the risk of flares during periods of relative stability, and controlling the less life- threatening, but often incapacitating day to day symptoms.
Journal ArticleDOI
Case records of the Massachusetts General Hospital.
Journal ArticleDOI
A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis
John N. Feder,Andreas Gnirke,Winston Thomas,Zenta Tsuchihashi,David A. Ruddy,A. Basava,F. Dormishian,R. Domingo,Michael C. Ellis,A. Fullan,L.M. Hinton,Norman Jones,B.E. Kimmel,Gregory S. Kronmal,Peter M. San Francisco Lauer,V.K. Lee,Deborah B. Loeb,Felipa A. Mapa,Erin E. McClelland,Nicole C. Meyer,Gabe Mintier,N. Moeller,T. E. Moore,E. Morikang,Cynthia E. Prass,Leah Quintana,Steven M. Starnes,Randall C. Schatzman,K.J. Brunke,Dennis Drayna,Neil Risch,Bruce R. Bacon,Roger K. Wolff +32 more
TL;DR: Using linkage-disequilibrium and full haplotype analysis, this paper identified a 250-kilobase region more than 3 megabases telomeric of the major histocompatibility complex (MHC) that is identical-by-descent in 85% of patient chromosomes.